Skip to main content

Table 9 Recommendations for follow-up

From: Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

Test Frequency Grade
SS-LCH And No Disease Activity
History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin changes, neurological symptoms) • Every clinic visit D2
Clinical assessment, blood count and blood chemistry (as described in baseline diagnostics), ultrasound • End of therapy D2
• every 6 month (for the next 2 years)
• then once a year (for at least 3 years)
Chest XR • annually (for at least 3 years) D2
After MS-LCH And With No Disease Activity
History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin changes, neurological symptoms) • Every clinic visit D2
Clinical assessment, blood count and blood chemistry (as described in baseline diagnostics), ultrasound • End of therapy D2
• every 3 month (for the next 2 years)
• every 6 month (for the next 3 years)
• then once a year (for at least 5 years)
Chest XR • annually (for at least 3 years) D2
TSH, freeT4 • Once a year (until end of routinely follow up) D2
Patients With Active Disease
Diagnostic procedures are depending on the site of organ involvement Frequency is depending on rates and velocity of recurrences D2
Patients With pLCH
History (in case of non-pulmonary symptoms: look for MS LCH, see Table 4) • Every clinic visit D2
Diagnostic procedures are depending on symptoms und course of PLCH (baseline: Chest X-ray, lung function (+DCLO) • End of therapy D2
• every 6 month (for the next 2 years)
• then once a year (for at least 5 years)